Prevalence and management of gastrointestinal complications in lung transplant patients:: MITOS study group

被引:31
作者
Bravo, C.
Gispert, P.
Borro, J. M.
de la Torre, M.
Martinez, J. M. Cifrian
Rozas, S. Fernandez
Goni, F. Zurbano
机构
[1] Hosp Valle De Hebron, Lung Transplant, Serv Pneumol, Barcelona 08035, Spain
[2] Hosp Juan Canalejo, La Coruna, Spain
[3] H Marques Valdecilla, Santander, Spain
关键词
D O I
10.1016/j.transproceed.2007.07.054
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction. No studies have yet been performed to evaluate the prevalence of gastrointestinal (GI) complications in solid organ transplant recipients in Spain. Materials and methods. An observational, cross-sectional study to evaluate the prevalence and management of GI complications in transplanted patients was conducted via a written questionnaire given to doctors at their practice. Results. A total of 58 lung transplant recipients were included. Their mean age was 52.6 +/- 10.8 years; 65% of the patients were men; and the mean time since the transplant was 2.1. +/- 2.3 years. GI complications were seen in 48.6% of the lung transplant patients. Regarding the management, the most frequently used measure was the prescription of gastric protectors (70.5%). In seven patients, the inummosuppressive treatment was also modified (reduced, discontinued temporarily, or discontinued permanently); however, the figure is so low that no conclusions can be drawn from this result. Conclusions. The prevalence of GI complications in lung transplant was over 50%, and these complications affected patients' daily activities in most cases. In lung transplant recipients, there was a higher prevalence of nausea and abdominal pain and a lower of diarrhea and dyspepsia than what was observed in other type of transplant recipients.
引用
收藏
页码:2409 / 2412
页数:4
相关论文
共 16 条
[1]   Review of the immunosuppressant enteric-coated mycophenolate sodium [J].
Budde, K ;
Glander, P ;
Diekmann, F ;
Waiser, J ;
Fritsche, L ;
Dragun, D ;
Neumayer, HH .
EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (06) :1333-1345
[2]   Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure [J].
Bunnapradist, Suphamai ;
Lentine, Krista L. ;
Burroughs, Thomas E. ;
Pinsky, Brett W. ;
Hardinger, Karen L. ;
Brennan, Daniel C. ;
Schnitzler, Mark A. .
TRANSPLANTATION, 2006, 82 (01) :102-107
[3]  
CARACENI P, 1995, ITAL J GASTROENTEROL, V27, P29
[4]   Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: A pilot study [J].
Dumortier, Jerome ;
Gagnieu, Marie-Claude ;
Salandre, Janine ;
Guillaud, Olivier ;
Guillem, Philipe ;
Adham, Mustapha ;
Boillot, Olivier .
LIVER TRANSPLANTATION, 2006, 12 (09) :1342-1346
[5]   Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil [J].
Hardinger, KL ;
Brennan, DC ;
Lowell, J ;
Schnitzler, MA .
TRANSPLANT INTERNATIONAL, 2004, 17 (10) :609-616
[6]  
Helderman JH, 2002, J AM SOC NEPHROL, V13, P277, DOI 10.1681/ASN.V131277
[7]   Prophylaxis and treatment of gastrointestinal complications following transplantation [J].
Helderman, JH .
CLINICAL TRANSPLANTATION, 2001, 15 :29-35
[8]   Gastrointestinal complications in lung transplant survivors that require surgical intervention [J].
Hoekstra, HJ ;
Hawkins, K ;
de Boer, WJ ;
Rottier, K ;
van der Bij, W .
BRITISH JOURNAL OF SURGERY, 2001, 88 (03) :433-438
[9]   Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients [J].
Hummel, Manfred ;
Yonan, Nizar ;
Ross, Heather ;
Miller, Leslie W. ;
Sechaud, Romain ;
Balez, Sebastien ;
Koelle, Ernst Ulrich ;
Gerosa, Gino .
CLINICAL TRANSPLANTATION, 2007, 21 (01) :18-23
[10]  
Lubetkin EI, 1996, AM J GASTROENTEROL, V91, P2382